Your browser is no longer supported. Please, upgrade your browser.
Settings
ATHX Athersys, Inc. daily Stock Chart
ATHX [NASD]
Athersys, Inc.
Index- P/E- EPS (ttm)-0.30 Insider Own9.70% Shs Outstand162.72M Perf Week-4.36%
Market Cap570.94M Forward P/E- EPS next Y-0.40 Insider Trans-1.59% Shs Float178.30M Perf Month14.46%
Income-47.30M PEG- EPS next Q-0.08 Inst Own17.60% Short Float8.15% Perf Quarter133.61%
Sales4.20M P/S135.94 EPS this Y-65.40% Inst Trans-2.54% Short Ratio2.87 Perf Half Y109.56%
Book/sh0.12 P/B23.75 EPS next Y-28.10% ROA-104.20% Target Price- Perf Year65.70%
Cash/sh0.16 P/C17.46 EPS next 5Y28.00% ROE-184.40% 52W Range1.13 - 4.38 Perf YTD131.71%
Dividend- P/FCF- EPS past 5Y-0.50% ROI- 52W High-34.93% Beta-1.75
Dividend %- Quick Ratio2.40 Sales past 5Y28.30% Gross Margin- 52W Low152.21% ATR0.27
Employees83 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)52.63 Volatility7.63% 9.72%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.30% Profit Margin- Rel Volume0.80 Prev Close2.97
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume5.07M Price2.85
Recom1.70 SMA200.87% SMA5010.99% SMA20075.01% Volume4,119,542 Change-4.04%
Aug-26-19Initiated Dawson James Buy $11
Feb-13-18Reiterated Maxim Group Buy $12 → $6
Aug-10-17Reiterated Maxim Group Buy $9 → $12
Feb-07-17Initiated Needham Buy $7
Mar-11-16Reiterated Maxim Group Buy $5 → $10
Jul-09-15Downgrade Piper Jaffray Overweight → Neutral
Jan-23-15Reiterated Maxim Group Buy $7 → $9
Apr-28-14Reiterated Maxim Group Buy $10 → $7
Dec-19-13Reiterated Maxim Group Buy $6 → $10
Oct-05-12Reiterated Maxim Group Buy $3 → $6
May-31-12Initiated Maxim Group Buy $3
Sep-13-10Reiterated WBB Securities Strong Buy $8 → $9
Jul-30-10Upgrade WBB Securities Buy → Strong Buy $8
Apr-12-10Initiated Brean Murray Buy $8
Nov-11-08Reiterated Leerink Swann Outperform $8 → $4
Sep-17-08Initiated Leerink Swann Outperform $8
Aug-01-08Initiated Canaccord Adams Buy $6
Jun-19-08Initiated Lazard Capital Buy $7
Jun-02-08Initiated Cowen & Co Outperform
May-18-20 06:00AM  Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference Business Wire
May-09-20 10:01PM  Athersys (ATHX) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 07:35PM  Edited Transcript of ATHX earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents +7.98%
May-07-20 04:05PM  Athersys Reports First Quarter 2020 Results Business Wire
04:00PM  Dawson James Sticks to Their Buy Rating for Athersys Investing.com
01:44PM  Exclusive: U.S. companies got emergency government loans despite having months of cash Reuters
May-06-20 02:32PM  Analyst Believes Potential COVID-19 Treatment Can Push Ahersys (ATHX) Stock up to $12 SmarterAnalyst
May-05-20 06:00AM  Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS Business Wire
May-04-20 11:19AM  Here's Why Athersys Tumbled 23.3% in April Motley Fool +7.35%
May-01-20 06:00AM  Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS Business Wire +6.52%
Apr-29-20 02:47PM  Athersys to Present at the Bank of America Merrill Lynch Virtual Healthcare Conference on May 14 Business Wire
Apr-28-20 06:40AM  Are Stem Cells the COVID-19 Treatment We've All Been Waiting For? Motley Fool -6.83%
Apr-22-20 12:00AM  The Notorious PPP Financial Times
Apr-21-20 08:00AM  Athersys to Host First Quarter Financial Results Call Business Wire
Apr-20-20 04:05PM  Athersys Announces Closing of Public Offering of Common Stock Business Wire +6.76%
Apr-15-20 09:33PM  Athersys Announces Pricing of Public Offering of Common Stock Business Wire
04:27PM  Athersys Announces Proposed Public Offering of Common Stock Business Wire
11:47AM  FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients Business Wire
08:03AM  The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US Benzinga
Apr-14-20 02:15PM  Edited Transcript of ATHX earnings conference call or presentation 16-Mar-20 8:30pm GMT Thomson Reuters StreetEvents -10.40%
08:37AM  Will Stem Cell Therapies Aid in Fight Against Coronavirus? Zacks
Apr-13-20 09:54AM  Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics Benzinga +18.90%
08:03AM  Athersys Jumps More Than 20% After FDA Approves MultiStem Coronavirus Study SmarterAnalyst
06:14AM  Athersys's stock shoots up after FDA OKs study for COVID-19-induced respiratory distress treatment MarketWatch
06:00AM  FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome Business Wire
Mar-30-20 06:00AM  HEALIOS K.K. Increases Investment in Athersys by Fully Exercising Warrant to Acquire Additional Shares Business Wire +32.14%
Mar-26-20 10:15AM  Here's Why We're Watching Athersys's (NASDAQ:ATHX) Cash Burn Situation Simply Wall St. +5.49%
Mar-19-20 06:00AM  Athersys Names Maia Hansen Senior Vice President, Operations and Supply Chain Business Wire +30.28%
Mar-16-20 04:05PM  Athersys Announces Financial Results for Fourth Quarter and Full Year 2019 Business Wire
02:30PM  Athersys, Inc. to Host Earnings Call ACCESSWIRE
Mar-09-20 09:58AM  Needham: 3 Stocks to Count on If the Coronavirus Crisis Continues TipRanks +16.53%
Feb-10-20 08:00AM  Athersys to Host Year-End 2019 Financial Results Call Business Wire
Feb-03-20 06:00AM  Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-24-20 05:36AM  How Much Did Athersys, Inc.'s (NASDAQ:ATHX) CEO Pocket Last Year? Simply Wall St.
Jan-15-20 08:22AM  The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga
06:00AM  Athersys Names Ivor Macleod Chief Financial Officer GlobeNewswire
Jan-14-20 06:00AM  Athersys Provides Update on One-Year ARDS Study Data GlobeNewswire
Dec-19-19 04:56PM  Hedge Funds Staying Clear Of Athersys, Inc. (NASDAQ:ATHX) Insider Monkey
Nov-25-19 11:22PM  Edited Transcript of ATHX earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-14-19 06:00AM  Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program GlobeNewswire
Nov-11-19 09:30AM  Were Hedge Funds Right About Souring On Athersys, Inc. (ATHX)? Insider Monkey
Nov-06-19 04:05PM  Athersys Reports Third Quarter 2019 Results GlobeNewswire
Nov-03-19 07:47AM  Did You Manage To Avoid Athersys's (NASDAQ:ATHX) 36% Share Price Drop? Simply Wall St.
Oct-14-19 01:00PM  Athersys to Host Third Quarter Financial Results Call GlobeNewswire
Sep-25-19 08:00AM  Athersys to Present at 2019 Cell & Gene Meeting on the Mesa GlobeNewswire
Sep-19-19 08:37AM  Athersys, Inc. (NASDAQ:ATHX): Is It Growing Too Fast? Simply Wall St.
Sep-05-19 11:22AM  Edited Transcript of ATHX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 11:23AM  Athersys (ATHX) Q2 2019 Earnings Call Transcript Motley Fool -5.93%
Aug-07-19 04:05PM  Athersys Reports Second Quarter 2019 Results GlobeNewswire
Jul-31-19 02:32PM  Do Institutions Own Shares In Athersys, Inc. (NASDAQ:ATHX)? Simply Wall St.
Jul-08-19 11:00AM  Athersys to Host Second Quarter Financial Results Call GlobeNewswire
Jun-20-19 09:58AM  Aggie Square executive helps foster university startups American City Business Journals
Jun-13-19 08:01AM  Edited Transcript of ATHX earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-04-19 06:00AM  Athersys to Present at Jefferies 2019 Healthcare Conference GlobeNewswire
May-28-19 06:00AM  Athersys to Participate in four Events at the International Society of Cell and Gene Therapy Conference GlobeNewswire
May-24-19 01:46PM  Volatility 101: Should Athersys (NASDAQ:ATHX) Shares Have Dropped 25%? Simply Wall St.
May-20-19 12:15PM  Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference GlobeNewswire -5.58%
May-18-19 09:50AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
May-14-19 03:54PM  Here's Why Athersys Rose as Much as 15.2% Today Motley Fool +13.92%
May-09-19 11:23AM  Athersys (ATHX) Q1 2019 Earnings Call Transcript Motley Fool
May-08-19 04:05PM  Athersys Reports First Quarter 2019 Results GlobeNewswire
02:30PM  Athersys, Inc. to Host Earnings Call ACCESSWIRE
Apr-23-19 04:08PM  Here's Why Athersys Is Soaring Today Motley Fool +16.08%
09:00AM  Athersys (ATHX) Upgraded to Strong Buy: Here's What You Should Know Zacks
06:00AM  HEALIOS K.K. Announces Enrollment of First Patient in Japan in the ONE-BRIDGE Study of MultiStem® Treatment for Acute Respiratory Distress Syndrome GlobeNewswire
Apr-15-19 10:00AM  Athersys to Host Investor Day in New York City GlobeNewswire
Apr-10-19 02:00PM  Athersys to Host First Quarter Financial Results Call GlobeNewswire
Mar-20-19 08:08AM  Edited Transcript of ATHX earnings conference call or presentation 14-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Mar-19-19 12:03PM  What Makes Athersys (ATHX) a New Buy Stock Zacks
Mar-14-19 07:16PM  Athersys Inc (ATHX) Q4 2018 Earnings Conference Call Transcript Motley Fool
05:04PM  Athersys Announces Financial Results for Fourth Quarter and Full Year 2018 GlobeNewswire
02:30PM  Athersys, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-19 08:57AM  Athersys (ATHX) Q4 Earnings: What's in Store for the Stock? Zacks
Feb-27-19 11:04AM  Is Athersys, Inc.s (NASDAQ:ATHX) CEO Paid Enough Relative To Peers? Simply Wall St.
Feb-14-19 08:00AM  Athersys to Host Year-End 2018 Financial Results Call GlobeNewswire
Jan-24-19 02:20PM  Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study Zacks
Jan-23-19 09:27AM  Athersys (ATHX) Upgraded to Buy: What Does It Mean for the Stock? Zacks +14.39%
06:00AM  Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS) GlobeNewswire
Dec-17-18 06:00AM  Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China GlobeNewswire -10.42%
Dec-03-18 12:18PM  Edited Transcript of ATHX earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-13-18 12:29PM  Are Athersys Incs (NASDAQ:ATHX) Interest Costs Too High? Simply Wall St.
Nov-06-18 04:05PM  Athersys Reports Third Quarter 2018 Results GlobeNewswire
Oct-29-18 08:45AM  Market Trends Toward New Normal in Crown, Athersys, CSX, Magellan Health, Spectrum Brands, and MGIC Investment Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-09-18 04:00PM  Athersys to Host Third Quarter Financial Results Call GlobeNewswire
Oct-08-18 10:07AM  Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7% Zacks
Oct-04-18 03:18PM  Alnylam Files Clinical Trial Application for ALN-AAT02 in UK Zacks
Oct-03-18 11:59AM  Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo Zacks
Oct-02-18 10:30AM  Global Stem Cell Market Expected to Reach $270.5 Billion ACCESSWIRE
Sep-24-18 06:00AM  Athersys to Present at 2018 Cell & Gene Meeting on the Mesa GlobeNewswire
Sep-20-18 11:14AM  Who Are The Major Shareholders Of Athersys Inc (NASDAQ:ATHX)? Simply Wall St.
Sep-14-18 09:09AM  The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion Zacks
Sep-13-18 09:14AM  IPOs and Foreign Investment Propel Biotech: 4 Top Picks Zacks
Aug-21-18 09:50PM  Edited Transcript of ATHX earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-16-18 09:30AM  Is Athersys (ATHX) Stock Outpacing Its Medical Peers This Year? Zacks
Aug-14-18 07:30AM  Recent Analysis Shows Williams Partners, GameStop, Opko Health, Athersys, CSX, and Kratos Defense & Security Solutions Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-07-18 04:05PM  Athersys Reports Second Quarter 2018 Results GlobeNewswire
02:30PM  Athersys, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-18 06:00AM  Athersys Makes Important Leadership Hire to Carry Out Its Manufacturing Strategy GlobeNewswire
Jul-31-18 06:00AM  Athersys Announces Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem® Treatment for Ischemic Stroke GlobeNewswire +6.38%
Jul-12-18 10:30AM  Biotechnology Companies Involved in Regenerative Medicine ACCESSWIRE
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Campbell Laura KSenior Vice Pres FinanceApr 01Sale3.81137,894525,395371,628Apr 01 06:01 PM
Campbell Laura KSenior Vice Pres FinanceMar 31Sale2.9051,483149,357509,522Apr 01 06:01 PM
Campbell Laura KSenior Vice Pres FinanceMar 30Sale2.4044,929107,834561,005Apr 01 06:01 PM
Lehmann William JRPresident and COOMar 18Sale1.3930,00041,679425,645Mar 18 05:12 PM
Harrington John JExec Vice Pres and CSOMar 17Sale1.325,0006,586688,220Mar 18 04:26 PM
Harrington John JExec Vice Pres and CSOMar 16Sale1.255,0006,254693,220Mar 18 04:26 PM
Lehmann William JRPresident and COODec 18Sale1.1730,00035,202469,636Dec 18 05:22 PM
Harrington John JExec Vice Pres and CSODec 17Sale1.225,0006,103715,060Dec 18 04:46 PM
Harrington John JExec Vice Pres and CSODec 16Sale1.245,0006,185720,060Dec 18 04:46 PM
Lehmann William JRPresident and COOSep 18Sale1.4430,00043,260512,196Sep 19 11:18 AM
Van Bokkelen GilChairman and CEOAug 12Option Exercise1.2820,00025,6001,595,949Aug 14 10:51 AM
Lehmann William JRPresident and COOJun 18Sale1.8020,00036,090554,952Jun 18 05:13 PM